Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance

Current Opinion in Organ Transplantation

Volumn 15, Issue 4, 2010, Pages 411-415

  Hanidziar, Dusan ^a   Koulmanda, Maria ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

inflammation; regulatory T cells; Th17 cells

Indexed keywords

ALEMTUZUMAB; CD39 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFLAMMATORY AGENT; AUTACOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17;

AUTOIMMUNE DISEASE; CELL DEATH; GRAFT REJECTION; HUMAN; HYPOXIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; ISCHEMIA; LYMPH NODE; LYMPHOCYTOPENIA; NONHUMAN; PROTEIN STABILITY; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TRANSPLANTATION TOLERANCE; ALLOTRANSPLANTATION; ANIMAL; DRUG EFFECTS; GRAFT SURVIVAL; HELPER CELL; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-17; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955230058     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833b7929     Document Type: Review

References (53)

1. Salama AD, Womer KL, Sayegh MH. Clinical transplantation tolerance: many rivers to cross. J Immunol 2007; 178:5419-5423.
2. Turka LA, Lechler RI. Towards the identification of biomarkers of transplantation tolerance. Nat Rev Immunol 2009; 9:521-526.
3. Strom TB. 2006 Homer W. Smith lecture: taming T cells. J Am Soc Nephrol 2007; 18:2824-2832.
4. Feng G, Chan T, Wood KJ, Bushell A. Donor-reactive regulatory T-cells. Curr Opin Organ Transplant 2009; 14:432-438.
5. Yeung MY, Sayegh MH. Regulatory T cells in transplantation: what we know and what we do not know. Transplant Proc 2009; 41 (6 Suppl):S21-S26.
6. Steward-Tharp SM, Song YJ, Siegel RM, O'Shea JJ. New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci 2010; 1183:123-148.
7. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7:1722-1732.
8. Raimondi G, Sumpter TL, Matta BM, et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote longterm graft survival in immunocompetent recipients. J Immunol 2010; 184:624-636.
9. Strom TB, Koulmanda M. Cytokine related therapies for autoimmune disease. Curr Opin Immunol 2008; 20:676-681.
10. Strom TB, Koulmanda M. Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol 2009; 20:1677-1680.
11. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238.
12. Korn T, Bettelli E, Gao W, et al. IL-21initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448:484-487.
13. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009; 9:883-889.
14. Kruger B, Krick S, Dhillon N, et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 2009; 106:3390-3395.
15. Huang X, Moore DJ, Ketchum RJ, et al. Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Endocrine Rev 2008; 29:603-630.
16. Millington TM, Madsen JC. Innate immunity in heart transplantation. Curr Opin Organ Transplant 2009; 14:571-576.
17. Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion injury. Transplant Rev (Orlando) 2009; 23:1-10.
18. Karim M, Kingsley CI, Bushell AR, et al. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004; 172:923-928.
19. Chen L, Ahmed E, Wang T. TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol 2009; 182:6217-6225.
20. Mitchell P, Afzali B, Lombardi G, Lechler RI. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplantat 2009; 14:326-331.
21. Yang J, Brook MO, Carvalho-Gaspar M, et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A 2007; 104:19954-19959.
22. Mills KHG. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008; 38:2636-2649.
23. Van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007; 27:660-669.
24. Burrell BE, Csencsits K, Lu G, et al. CD8+ Th17 mediate costimulation blockade-resistant allograft rejection in T-bet-deficient mice. J Immunol 2008; 181:3906-3914.
25. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205:3133-3144.
26. Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009; 21:612-618.
27. Walker LS. Regulatory T-cells overturned: the effectors fight back. Immunology 2009; 126:466-474.
28. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009; 10:689-695.
29. Kim JI, Lee MKT, Moorec DJ, et al. Regulatory T-cell counter-regulation by innate immunity is a barrier to transplantation tolerance. Am J Transplant 2009; 9:2736-2744.
30. Chauhan SK, Saban DR, Lee HK, Dana R. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol2009; 182:148-213.
31. Yang XO, Nurieva R, MartinezGJ, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29:44-56.
32. Radhakrishnan S, Cabrera R, Schenk EL, et al. Reprogrammed FoxP3+ T-regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol 2008; 181:3137-3147.
33. Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009; 131:298-307.
34. Fletcher JM, Lonergan R, Costelloe L, et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183:7602-7610.
35. Padiyar A, Augustine JJ, Hricik DE. Induction antibody therapy in kidney transplantation. Am J Kidney Dis 2009; 54:935-944.
36. Turka LA, Walsh PT. IL-2 signaling and CD4+CD25+Foxp3+ regulatory T cells. Front Biosci 2008; 13:1440-1446.
37. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A 2009; 106:1903-1908.
38. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10:1000-1007.
39. Duarte JH, Zelenay S, Bergman ML, et al. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol 2009; 39:948-955.
40. Koulmanda M, Budo E, Bonner-Weir S, et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A 2007; 104:13074-13079.
41. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-1036.
42. Wan S, Xia C,Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+T cell regulatory functions. J Immunol 2007; 178:271-279.
43. Nagar M, Jacob-Hirsch J, Vernitsky H, et al. TNF activates a NF-kappaBregulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol 2010; 184:3570-3581.
44. Korn T, Reddy J, Gao W, et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007; 13:423-431.
45. Ayyoub M, Deknuydt F, Raimbaud I, et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci U S A 2009; 106:8635-8640.
46. Tartar DM, VanMorlan AM, Wan X, et al. FoxP3+RORgammat+ T helper intermediates display suppressive function against autoimmune diabetes. J Immunol 2010; 184:3377-3385.
47. Oldenhove G, Bouladoux N, Wohlfert EA, et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009; 31:772-786.
48. Koch MA, Tucker-Heard G, et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009; 10:595-602.
49. Zheng Y, Chaudhry A, Kas A, et al. Regulatory T-cell suppressor program coopts transcription factor IRF4 to control T(H)2 responses. Nature 2009; 458:351-356.
50. Lynch RJ, Platt JL. Escaping from rejection. Transplantation 2009; 88:1233-1236.
51. Koulmanda M, Bhasin M, Hoffman L, et al. Curative and beta cell regenerative effects of alpha1 antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A 2008; 105:16242-16247.
52. Lewis EC, Mizrahi M, Toledano M, et al. Alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A 2008; 105:16236-16241.
53. Ouyang W, Filvaroff E, Hu Y, Grogan J. Novel therapeutic targets along the Th17 pathway. Eur J Immunol 2009; 39:634-675.